BioNTech SE at JPMorgan Healthcare Conference Transcript - Thomson StreetEvents

BioNTech SE at JPMorgan Healthcare Conference Transcript

BioNTech SE at JPMorgan Healthcare Conference Transcript - Thomson StreetEvents
BioNTech SE at JPMorgan Healthcare Conference Transcript
Published Jan 15, 2020
16 pages (8604 words) — Published Jan 15, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of BNTX.OQ presentation 15-Jan-20 3:30pm GMT

  
Brief Excerpt:

...Good morning, everyone, and welcome to the third day of the JPMorgan Healthcare Conference. My name is Matthew Holt, and I'm a member on the biotech equity research team here at JPMorgan. It's my pleasure to introduce our next presenting company, BioNTech. And presenting today for BioNTech will be CEO and Co-Founder, Ugur Sahin. And please note that following Ugur's presentation, there's a breakout room in the Yorkshire room across the hall. So with that, I'll hand it over to Ugur. Ugur Sahin ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
BioNTech SE
Ticker
BNTX.OQ
Time
3:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst : The (inaudible) break out. Yes. All right. Should we get going then? Do you want to introduce yourself?

Question: Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst : I'll start out asking the first question, and then I'll hand it over to [agency.] But in regards to all you know about your iNeST programs, including the updates you provided today, I'm curious if you could just like help frame your thoughts on where you see iNeST most appropriately suited for, like whether it's in the adjuvant or the metastatic setting? And then also, given your very initial combination commentary with pembroizumab. Just how do you see these programs as monotherapies or being used in combination? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JANUARY 15, 2020 / 3:30PM, BNTX.OQ - BioNTech SE at JPMorgan Healthcare Conference

Question: Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst : Yes. Does any one have a question they want to ask? Unidentified Participant So you approach (inaudible) composites on the T cell. But very frequently, we can see that (inaudible) in patients towards that in patients, particularly, relates (inaudible) tumors. So can you give any idea of how you can outcomes those things with your product.

Question: Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst : Okay. And then as I guess, maybe just moving to the next modality CAR-T therapy, for your CLDN6 CAR-T program, why specifically try or decide to pursue CAR-T as opposed to the other modalities you have in your pipeline in this target?

Question: Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst : Great. So I think we're pretty much out of time. So I guess, maybe one more question. Unidentified Participant With respect to the mRNA, (inaudible) of your platform, how do differ from (inaudible) and do you have freedom to operate? Forgive me if you already discussed this.

Question: Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst : Great. Thank you so much.

Table Of Contents

BioNTech SE at UBS Global Healthcare Conference (Virtual) Transcript – 2020-05-19 – US$ 54.00 – Edited Transcript of BNTX.OQ presentation 19-May-20 4:30pm GMT

BioNTech SE at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript – 2020-05-14 – US$ 54.00 – Edited Transcript of BNTX.OQ presentation 14-May-20 3:40pm GMT

BioNTech SE Q1 2020 Earnings Call Transcript – 2020-05-12 – US$ 54.00 – Edited Transcript of BNTX.OQ earnings conference call or presentation 12-May-20 12:00pm GMT

BioNTech SE - Special Call Transcript – 2020-04-23 – US$ 54.00 – Edited Transcript of BNTX.OQ conference call or presentation 23-Apr-20 12:00pm GMT

Full Year 2019 BioNTech SE Earnings Call Transcript – 2020-03-31 – US$ 54.00 – Edited Transcript of BNTX.OQ earnings conference call or presentation 31-Mar-20 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "BioNTech SE at JPMorgan Healthcare Conference Transcript" Jan 15, 2020. Alacra Store. May 11, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/BioNTech-SE-at-JPMorgan-Healthcare-Conference-T12980667>
  
APA:
Thomson StreetEvents. (2020). BioNTech SE at JPMorgan Healthcare Conference Transcript Jan 15, 2020. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/BioNTech-SE-at-JPMorgan-Healthcare-Conference-T12980667>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.